U.S. markets closed

ADMA Biologics, Inc. (ADMA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.4500+0.0500 (+2.08%)
At close: 04:00PM EDT
2.4600 +0.01 (+0.41%)
After hours: 05:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close2.4000
Bid2.4000 x 28000
Ask2.4700 x 21500
Day's Range2.3500 - 2.4700
52 Week Range1.0100 - 2.4800
Avg. Volume2,604,825
Market Cap481.075M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-0.4900
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ADMA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ADMA Biologics Inc
    Analyst Report: Baxter International Inc.Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. The company offers contract manufacturing services to pharmaceutical companies. The Hillrom transaction has added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's 2021 revenue came from more digitally connected offerings like its smart beds and Voalte medical communications app.
    Fair Value
    Economic Moat
    20 days agoMorningstar
View more
  • Motley Fool

    Why ADMA Biologics Stock Triumphed on Thursday

    ADMA Biologics (NASDAQ: ADMA), typically one of the more under-the-radar coronavirus stocks, was very much on the radar of many investors on Thursday. ADMA attracted a degree of renown in 2020 after its convalescent plasma won Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) to fight COVID. As for the bottom line, ADMA booked a net loss of nearly $14 million ($0.07 per share).

  • Zacks

    Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates

    Adma Biologics (ADMA) delivered earnings and revenue surprises of 22.22% and 8.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update

    2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022 Narrowed 2Q2022 Net Losses to $13.8 Million, a 45% Improvement Over 1Q2022 Full Year 2022 Total Revenues Expected to Exceed $130 Million Gross Margin Growth and Narrowing Net Losses Expected Throughout 2022 and Beyond Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA)